Cigna Announced a New Agreement for Copay Caps on Eli Lilly and Novo Nordisk Weight Loss Drugs

The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit insured customers’ monthly out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy to $200.

A healthcare team discussing strategies for patient advocacy programs.

Beginning in the second half of 2025, the program targets businesses that do not already cover these drugs because of their high price tag. Harold Carter, senior vice president at Evernorth, stated the agreement guarantees uniform pricing for pharmacies and Evernorth’s home delivery while streamlining pre-authorization. The GLP-1 drugs are currently only covered by half of The Cigna Group (NYSE:CI)’s clients. Customers who now provide coverage could save as much as 20%.

The agreement comes after Lilly’s Zepbound was essentially sidelined when CVS Caremark said in April that Wegovy was its preferred weight-loss medication.

According to analysts, net discounts for employers on list prices range from 30% to 50%. Zepbound lists at $1,100 with a $725 net price; Wegovy lists at $1,350/month but averaged $616 net in March. When compared to cash expenditures made out of pocket, the new caps offer savings of over 50%. Evernorth’s action is in advance of the Inflation Reduction Act’s 2027 Medicare drug pricing reductions, which will benefit Novo’s products. Eli Lilly states that it remains committed to expanding industry collaboration to improve access to Zepbound.

While we acknowledge the potential of CI to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than CI and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.